VRCA — Verrica Pharmaceuticals Inc. catalysts
Next verified catalyst
2026-11-01 — Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11 (month) in 8d
ESTIMATED |
READOUT
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2
Phase 3 · Common Warts, Common Warts (Verruca Vulgaris) |
VRCA Verrica Pharmaceuticals Inc. | VP-102, Vehicle |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-24
Sponsor-projected date — can change
|